MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Inflammation"

  • 2023 International Congress

    Protective effect and mechanism of TREM2 in Parkinson’s disease with cognitive impairment

    P. Zhang, Y. Zhang (Guanzhou, China)

    Objective: this study explored whether TREM2 plays a protective role in PD with cognitive impairment by promoting the activation of DAM. Background: The latest research…
  • 2023 International Congress

    Plasma biomarkers in iRBD patients serve as potential markers of early PD and motor severity

    B. Huxford, C. Simonet-Hernandez, L. Pérez-Carbonell, A. Schrag, R. Dobson, A. Noyce (London, United Kingdom)

    Objective: We aimed  to investigate biomarkers of inflammation and neuroaxonal damage in people with isolated REM sleep behaviour disorder (iRBD) compared to controls, and understand…
  • 2023 International Congress

    Montelukast as disease modifying treatment for Parkinson’s disease: a pilot study.

    J. Wallin, P. Svenningsson (Stockholm, Sweden)

    Objective: To assess safety and tolerability of high dose Montelukast as a possible disease modifying treatment for Parkinson’s disease. Background: Emerging evidence suggests that the…
  • 2023 International Congress

    Preliminary Report on the efficacy of Allogeneic Bone marrow-derived Mesenchymal Stem Cells as a disease-modifying therapy for idiopathic Parkinson’s disease: Phase IIa double-blind, randomized controlled trial.

    M. Schiess, J. Suescun, C. Green, E. Tharp, S. Chandra, C. Adams, M. Shahnawaz, E. Rodarte, V. Thyne, T. Ellmore (Houston, USA)

    Objective: To select the safest and most effective number of repeat doses of allogeneic mesenchymal stem cells (MSC) delivered intravenously to slow the progression of…
  • 2023 International Congress

    Preliminary Report on the Safety and Tolerability of Allogeneic Bone marrow-derived Mesenchymal Stem Cells as a disease-modifying therapy for Parkinson’s disease: Phase IIa double-blind, randomized controlled trial

    J. Suescun, T. Ellmore, C. Adams, V. Thyne, E. Tharp, S. Chandra, C. Green, R. Shastri, J. Saltarrelli, M. Schiess (Houston, USA)

    Objective: To select the safest and most effective number of repeat doses of allogeneic mesenchymal stem cells (MSC) purified from bone marrow-derived from a healthy…
  • 2023 International Congress

    Parkinson’s Disease and Chronic Inflammatory Demyelinating Polyneuropathy: Broadening the Clinical Spectrum of VCP Mutations?

    E. Contaldi, L. Magistrelli, R. Cantello, S. Gallo, F. Vignaroli (Novara, Italy)

    Objective: Valosin-containing protein (VCP) mutation causes a multiorgan disease characterized by inclusion body myopathy, Paget disease and frontotemporal dementia, more rarely by Charcot-Marie-Tooth disease type…
  • 2022 International Congress

    Increased Prevalence of Thyroid Disease in Cervical Dystonia

    L. Scorr, G. Kilic-Berkmen, A. Rosen, C. Yeo, J. Hanfelt, H. Jinnah (Atlanta, USA)

    Objective: This study evaluated the hypothesis that autoimmune disorders may be more common in cervical dystonia (CD) than neurological controls. Background: Although there are many…
  • 2022 International Congress

    Phosphorylated α-synuclein at serine residue 129 decreased in Parkinson’s disease patients taking 250mg of daily niacin for six months

    C. Wakade, M. Seamon, S. Purohit, J. Morgan, R. Chong (Augusta, USA)

    Objective: The main objective was to determine if α-synuclein could be modulated by niacin supplementation, contributing to improved Parkinson’s disease (PD) symptoms. Background: Niacin supplementation…
  • 2022 International Congress

    A Phase 1b study to test the safety, pharmacokinetics, and pharmacodynamics of a novel inflammasome inhibitor in early-stage Parkinson’s disease: Rationale and study design

    G. D'Urso, A. Thomann, J. Anzures-Cabrera, B. Zinnhardt, B. Ricci, M. Marchesi, V. Machado, E. Mracsko, N. Pavese, K. Marek, K. Brockmann, T. Simuni, N. Milani Muelhardt, G. Pagano (Basel, Switzerland)

    Objective: To describe the study design of a Phase 1b to test the safety, pharmacokinetics, and pharmacodynamics of a novel inflammasome inhibitor in individuals with…
  • 2022 International Congress

    4 YEARLONG POST PARTUM AUTOIMMUNE CHOREA AS INITIAL PRESENTATION OF INCOMPLETE SLE/APS

    W. Trillo Alvarez, J. Medina Suárez, J. Molina Acosta, A. Escalante Mercado, C. Ibañez Escalante, E. Carrillo Monteagudo, V. Medina Cerpa, E. Ramos Luza, P. Gonzales Romero, G. García Huamán (AREQUIPA, Peru)

    Objective: The aim is to report a case of a 4 yearlong postpartum autoimmune chorea secondary to incomplete SLE/APS. Background: Chorea is a movement disorder…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 22
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • An atypical and interesting feature of Parkinson´s disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley